The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome by Alviggi, Carlo et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and
Hyperandrogenism-Related Polycystic Ovarian Syndrome
Alviggi, Carlo; Conforti, Alessandro; De Rosa, Pasquale; Strina, Ida; Palomba, Stefano;
Vallone, Roberta; Gizzo, Salvatore; Borrelli, Rosaria; Andersen, Claus Yding; De Placido,
Giuseppe; Guerriero, Stefano
Published in:
Frontiers in Endocrinology
DOI:
10.3389/fendo.2017.00117
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Alviggi, C., Conforti, A., De Rosa, P., Strina, I., Palomba, S., Vallone, R., ... Guerriero, S. (2017). The
Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related
Polycystic Ovarian Syndrome. Frontiers in Endocrinology, 8, [117]. https://doi.org/10.3389/fendo.2017.00117
Download date: 03. Feb. 2020
May 2017 | Volume 8 | Article 1171
Original research
published: 31 May 2017
doi: 10.3389/fendo.2017.00117
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Amanda M. De Mestre, 
Royal Veterinary College, 
United Kingdom
Reviewed by: 
Livio Casarini, 
University of Modena and 
Reggio Emilia, Italy  
Nikolaos P. Polyzos, 
USP Institut Universitari Dexeus, 
Spain
*Correspondence:
Carlo Alviggi 
alviggi@unina.it
Specialty section: 
This article was submitted 
to Reproduction, 
a section of the journal 
Frontiers in Endocrinology
Received: 09 January 2017
Accepted: 12 May 2017
Published: 31 May 2017
Citation: 
Alviggi C, Conforti A, De Rosa P, 
Strina I, Palomba S, Vallone R, 
Gizzo S, Borrelli R, Andersen CY, 
De Placido G and Guerriero S (2017) 
The Distribution of Stroma and 
Antral Follicles Differs between 
Insulin-Resistance and 
Hyperandrogenism-Related 
Polycystic Ovarian Syndrome. 
Front. Endocrinol. 8:117. 
doi: 10.3389/fendo.2017.00117
The Distribution of stroma and antral 
Follicles Differs between insulin-
resistance and hyperandrogenism-
related Polycystic Ovarian 
syndrome
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Roberta Vallone1, Salvatore Gizzo 2, Rosaria Borrelli1, Claus Yding Andersen 3,  
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Gynecology, Policlinico Universitario Duilio Casula, University of Cagliari, Cagliari, Italy
introduction: Although insulin resistance plays an important pathogenetic role in 
polycystic ovary syndrome (PCOS), no correlation between ultrasound PCOS pattern 
and insulin resistance has yet been reported. The aim of this retrospective observational 
study was to assess whether the ovarian ultrasonographic parameter differed between 
PCOS women with insulin resistance and those with a hyperandrogenic profile.
Materials and methods: Women who fulfilled the Rotterdam criteria for PCOS were 
retrospectively studied. Anthropometric, biochemical, and clinical data were recorded. 
Women were divided into two groups based on specific transvaginal ultrasound param-
eters: subjects with more than half of the follicles measuring between 5 and 9 mm in 
diameter, an ultrasonographic determined stroma/total area (S/A) > 0.34 and a “necklace” 
sign of antral follicles (Group A); and subjects with more than half of the antral follicles 
measuring between 2 and 4 mm in diameter, an S/A ≤ 0.34; no “necklace” sign but ubiq-
uitously distributed follicles determined by ultrasound (Group B). The association between 
these ultrasound patterns and the presence of insulin resistance was also evaluated.
results: Seventy-eight patients were enrolled: 33 with ultrasound sound pattern A and 45 
with pattern B. The latter pattern had a sensitivity of 88% and a specificity of 78% in predicting 
PCOS women with insulin resistance. There were no differences in age, Ferriman–Gallwey 
score, and serum gonadotropin or androgen levels between the two groups. Body mass 
index, the waist-to-hip ratio, and homeostasis model assessment were significantly higher 
in group B than in group A (p < 0.05). Conversely, sex hormone binding globulin levels and 
ovarian volume were significantly higher in group A (p < 0.05). Insulin resistance was more 
frequent in group B than in group A (36/41, 87.8% versus 7/32, 21.8%; p < 0.05).
conclusion: These results suggest that insulin resistance could be associated with a 
specific ultrasound pattern in PCOS patients.
Keywords: polycystic ovary syndrome, insulin resistance, ultrasound, hyperandrogenism, polycystic ovary
Figure 1 | example of median ovarian section with the ovarian and 
stromal total areas defined. Calipers are positioned so as to encircle the 
total gonad circumference (A1) and the stromal component circumference 
(A2). The stroma/total area was also calculated.
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inTrODucTiOn
Polycystic ovary syndrome (PCOS) is a common endocrine 
disease affecting approximately 5–10% of women of reproductive 
age (1). It is clinically characterized by anovulation, oligomenor-
rhea and hyperandrogenism, and polycystic ovary on ultrasound 
imaging (2). The ultrasound image of polycystic ovary is typically 
characterized by an ovarian volume of >10 cm3 and/or 12 or more 
follicles measuring 2–9 mm in diameter. Notably, enlarged ovar-
ian stroma is a marker of PCOS (3, 4). The stroma/total area (S/A) 
is another diagnostic tool for PCOS; it has a sensitivity of 100% 
and is highly correlated with plasma androgen level (5).
Insulin resistance is found in a high percentage of women 
affected by PCOS (6), although neither insulin resistance nor the 
metabolic syndrome is among the diagnostic criteria for PCOS 
established by the Rotterdam Consensus Group (7). There is 
evidence that the pathogenic mechanisms of insulin resistance-
related PCOS differ from those underlying hyperandrogenism-
related PCOS (6, 8). The diagnostic criteria for insulin resistance 
are much debated. Currently, the “gold standard” procedure for 
its diagnosis is the euglycemic clamp and the so-called “minimal 
model” (9). A less time-consuming method is homeostasis model 
assessment (HOMA) plus the co-presence of anthropometric 
alterations [body mass index (BMI) and the waist-to-hip ratio 
(WHR)] (9). Although insulin resistance plays an important 
pathogenetic role in PCOS (6), no correlation between ultrasound 
PCOS pattern and insulin resistance has yet been reported. PCOS 
women with insulin resistance are usually overweight and can be 
distinguished from PCOS women with androgenic features, slim 
appearance, and absence of insulin resistance. These two different 
“PCOS profiles” are consistent with Rotterdam criteria, however, 
their physiological and clinical phenotypes are macroscopically 
different.
The aim of this retrospective observational study was to 
assess whether the ovarian ultrasonographic parameter differed 
between PCOS women with insulin resistance and those with a 
hyperandrogenic profile.
MaTerials anD MeThODs
Patients
We evaluated PCOS patients who fulfilled Rotterdam criteria 
(7), attending the clinics of Endocrinology of Reproduction 
and Sterility-Infertility of our Department from January 2013 to 
December 2015. Considering that there is a dedicated ethic state-
ment below, we could delete this part because it is just a repeti-
tion. Anyway feel free to retain it on the basis of journal policy. No 
additional examination and blood testing were performed except 
for those required for patients’ assessment. All women signed a 
consent form for the evaluation of personal data. Inclusion crite-
ria were signs of polycystic ovaries, according to the most recent 
ESHRE/ASRM consensus criteria (2, 10). Exclusion criteria were 
as follows: basal follicle-stimulating hormone (FSH) > 10 IU/l; 
administration of estro-progestin or other hormonal treatment in 
the previous 6 months; congenital adrenal hyperplasia and other 
endocrine abnormalities; presence of ovarian formations with 
diameters > 14 mm in two ultrasound examinations carried at an 
interval of 30 days; thyroid disorders; diabetes mellitus; presence 
of a single ovary; and previous ovary surgery.
The patients’ anthropometric characteristics (weight, height, 
BMI, and WHR) were collected as well as serum levels of gonad-
otropins, DHEA-S, and free testosterone measured in the early 
follicular phase. We also evaluated hirsutism with the Ferriman–
Gallwey clinical score. All enrolled subjects underwent a 75-g 
oral glucose challenge and insulin measurements at baseline 
and 60, 120, and 180 min thereafter. We adopted strict criteria to 
define the “presence” or “absence” of ultrasonographic patterns 
related to insulin resistance. Thus, women were included in 
Group 1 (insulin resistance) only when all the following criteria 
were fulfilled: HOMA > 2.5 (9); BMI > 27 kg/m2; WHR > 0.85 
(11); sex hormone binding globulin (SHBG) serum levels below 
the 25th percentile (9, 11); and serum insulin >  150 IU/ml 
at 60  min and a change of <20% between 60 and 120  min 
after oral glucose load with 75  g of glucose (12). Similarly, 
only women whose values were within normal range served as 
control group [no-insulin resistance (Group 2)]. Consequently, 
women with an intermediate condition, namely those not 
showing the copresence or coabsence of all the aforementioned 
criteria were excluded from the study. In fact, taken separately, 
they could not be sufficiently specific to identify women with 
insulin resistance.
ultrasound Parameters
Pelvic ultrasound examination was carried out with a 6.5 MHz 
vaginal probe. The external circumferences of the ovary and the 
stroma were measured to determine the S/A ratio (Figure  1). 
The following sonographic parameters were recorded for 
each patient: total number of ovarian follicles with a diam-
eter < 10 mm; number of follicles with diameter between 2 and 
4  mm; the S/A ratio calculated with an ovarian median scan 
Figure 2 | sonographic pattern of a type a ovary (a). Note the typical rosary arrangement of follicles and the easily recognizable hyperechogenicity that results 
from thickening of theca (B). The stromal hypervascularity is clearly visible in (c). Secondary aspects are the dominance of follicles with a diameter of >4 mm and 
the predominance of longitudinal diameter (D).
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(5); and ovarian longitudinal (A), transverse (B), and coronal 
(C) diameters and volume [1/2 × (A × B × C)] (13). Based on 
these parameters, we arbitrarily defined two ultrasound pat-
terns (Figures  2 and 3): type A (Group A) characterized by 
>50% follicles with diameters between 5 and 9 mm and with an 
S/A > 0.34 (“necklace” sign defined by a hyperechoic central area 
and a rosary-like peripheral disposition of follicles) and type B 
(Group B) characterized by >50% follicles measuring 2–4 mm 
and with an S/A ≤  0.34 (no “necklace” sign and ubiquitously 
distributed follicles). Intermediate ultrasound patterns were not 
included in our analysis.
statistical analysis
Results are reported as mean ±  SD. The Student’s t-test or the 
Mann–Whitney U test was used for continuous variables with a 
parametric or no parametric distribution, respectively. Normal 
distribution of continuous variables was evaluated with the 
Shapiro test. Cohen’s kappa was used to evaluate the agreement 
between sonographers with respect to ultrasound ovarian pat-
tern. Sensitivity, specificity, positive predictive value, negative 
predictive value, and positive and negative likelihood ratio were 
calculated with the MedCalc statistic software to assess the accu-
racy of an ultrasound pattern in identifying PCOS patients with 
insulin resistance. The χ2 test was used to compare categorical 
data. A p < 0.05 was considered statistically significant. The SPSS, 
statistical software 18.0 (SPSS Inc., USA) was used to analyze data.
resulTs
Of the 309 patients affected by PCOS admitted to our institute, 
only women without an intermediate ultrasound profile and 
fulfilling inclusion and exclusion criteria were included for a total 
of 78 patients enrolled (Figure  4). Forty-one of these women 
met all the criteria of insulin resistance (Group 1); the remain-
ing 32 patients did not fulfill any insulin resistance criterion 
(Group 2). Five women with an intermediate metabolic profile 
were not included in our analysis (Figure  4). Demographic, 
anthropometric, hormonal, and ultrasound features of the two 
groups stratified according to insulin resistance are listed in 
Table 1. There was no difference in terms of age, androgen levels, 
or Ferriman–Gallwey score between the two groups. Women 
affected by insulin resistance were more likely to have a type B 
ultrasound pattern than women without insulin resistance (87.8 
versus 21.8%, p < 0.01).
The accuracy of the type B ultrasound pattern to identify 
PCOS women with insulin resistance was as follows: sensitivity 
0.88 CI 95% (0.74–0.96); specificity 0.78 CI 95% (0.60–0.91), 
positive likelihood ratio 4.01 CI 95% (2.06–7.80), negative 
likelihood ratio 0.16 CI 95% (0.07–0.36); and positive predic-
tive value 0.84 CI 95% (0.69–93.2), negative predictive value 
0.83 CI 95% (0.65–0.94). A Cohen’s kappa of 0.81, estimated 
in 50 subjects, indicated an excellent concordance between 
sonographers (14).
The demographic, anthropometric, and hormonal data of 
patients divided according to the ultrasound pattern of PCOS, 
including also five women with intermediate metabolic condi-
tion, are listed in Table 2. The mean age of patients, serum levels 
of gonadotropin, androgens, and the Ferriman–Gallwey score 
did not differ significantly between the two groups. Conversely, 
BMI, WHR, and HOMA values were significantly higher in 
patients with a B-type ultrasound pattern. Patients with an 
A-type pattern had higher SHBG levels (27.2  ±  11.3  nmol/l 
4Alviggi et al. Ultrasound in PCOS
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Figure 3 | sonographic pattern of a type B ovary (a). Note the ubiquitous arrangement of follicles and the absence of central echogenicity (B). Characteristic 
signs of the type B ovary are a more “globular” gonad versus a type A ovary (c), with attenuation of the typical dominance of longitudinal diameter and the presence 
of follicles with a mean diameter lower than those observed in type A (D).
versus 52.2 ± 21.1 nmol/l, p < 0.01) and a larger ovarian volume 
(14.6 ± 5.6 versus 11.9 ± 4.1 cm3, p < 0.05) than did patients with 
an A-type pattern.
DiscussiOn
We have identified an association between metabolic parameters 
and ultrasound pattern in patients affected by PCOS. BMI, WHR, 
and HOMA were significantly lower in patients with a type A 
ovary, namely those with the classical “necklace” sign than in 
women with a type B ovary. The association of a high HOMA 
with elevated anthropometric indices was previously reported 
to be an efficient positive predictor of insulin resistance (9). The 
association between insulin resistance and specific ultrasound 
patterns is supported by data obtained when we stratified our 
study population into patients with insulin resistance (Group 1) 
and patients without insulin resistance (Group 2). Type B ovaries 
were significantly more frequent in group 1 than in group 2. On 
the contrary, the classic ultrasound picture of PCOS (type A) was 
more frequent in Group 2 patients. Neither serum concentrations 
of androgens nor the Ferriman–Gallwey score differed between 
the two groups. However, all biochemical and clinical androgenic 
variables, including basal luteinizing hormone (LH), were higher 
in patients with a type A ovary than in those with a type B ovary, 
and the difference was almost significant in the case of 17-OH P 
concentrations (Table 2).
The different ovarian profiles observed in our study support 
the concept that the pathogenesis and clinical phenotype could 
differ between PCOS patients with hyperandrogenism and nor-
mal anthropometric parameters and PCOS patients with insulin 
resistance. In other words, two physiopathogenetic pathways, one 
characterized by hyperandrogenism and the other by insulin resist-
ance, could induce the same effects, namely, they could interfere 
with selection mechanisms of the dominant follicle and also induce 
atresia of secondary follicles. These changes in folliculogenesis 
could result in anovulation, arrest of multiple follicles at different 
developmental stages, and hyperandrogenism, which could be 
either primitive or secondary depending on clinical conditions.
Figure 4 | Flow chart of patients enrolled in the study standards for reporting Diagnostic accuracy.
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TaBle 1 | Demographic, anthropometric, and hormonal characteristics, 
and ultrasound pattern frequency in the study population stratified 
according to insulin resistance.
characteristics group 1 (n = 41) group 2 (n = 32) p-Value
Age (years) 28.6 ± 6 28.5 ± 4.8 0.93
BMI (kg/m2) 34.5 ± 5.9 23.5 ± 2.5 0.0001
WHR 0.9 ± 0.5 0.8 ± 0.8 0.0001
HOMA 5.1 ± 2.9 1.5 ± 0.6 0.0001
Type B ovary 36/41 (87.8%) 7/32 (21.8%) 0.0001
Type A ovary 5/41 (12.1%) 25/32 (78.1%) 0.0001
Ovarian volume (cm3) 14.6 ± 5.6 11.9 ± 4.1 0.024
SHBG (nmol/l) 27.2 ± 11.3 52.2 ± 21.1 0.0001
Ferriman–Gallwey score 10.7 ± 3.3 11.3 ± 3.2 0.47
Free testosterone (pg/ml) 2.5 ± 2.6 1.9 ± 1.5 0.36
DHEA-S (μg/dl) 282.1 ± 391.1 252.5 ± 304 0.74
17-OH-P (ng/ml) 1.2 ± 0.9 1.9 ± 1.7 0.93
Results reported as mean ± SD or percentage (%).
BMI, body mass index; WHR, waist-to-hip ratio; HOMA, homeostasis model 
assessment; SHBG, sex hormone binding globulin; 17-OH-P, 17-hydroxy 
progesterone.
TaBle 2 | Demographic, anthropometric, and hormonal characteristics 
of patients divided according to the ultrasound pattern of PcOs.
characteristics group a (type a 
ovary) (n = 33)
group B (type B 
ovary) (n = 45)
p-Value
Age (years) 28.4 ± 5.4 29 ± 5.8 0.61
BMI (kg/m2) 23.7 ± 2.3 43.1 ± 56 0.048
WHR 0.81 ± 0.6 0.92 ± 0.5 0.0001
HOMA 1.5 ± 0.8 4.9 ± 2.8 0.0001
LH (UI/l) 9.25 ± 6.3 5.2 ± 3.3 0.002
Ovary volume (cm3) 12.1 ± 4 14.3 ± 5.6 0.048
SHBG (nmol/l) 53.5 ± 23.5 28 ± 11.6 0.0001
Ferriman–Gallwey 11.6 ± 2.9 10.5 ± 3.4 0.14
Free testosterone (pg/ml) 2.6 ± 2.6 2.1 ± 1.7 0.27
DHEA-S (μg/dl) 224.7 ± 221.7 164.4 ± 109.2 0.14
17-OH-P (ng/ml) 1.8 ± 1.5 1.2 ± 1.3 0.057
Results are reported as mean ± SD.
BMI, body mass index; WHR, waist-to-hip ratio; HOMA, homeostasis model 
assessment; PCOM, polycystic ovarian morphology; LH, luteinizing hormone;  
SHBG, sex hormone binding globulin; 17-OH-P, 17-hydroxy progesterone.
Based on our preliminary data, the classical ultrasound imag-
ing characterized by a hyperechoic central area and a peripheral 
“necklace” arrangement of follicles is more typically observed in 
PCOS patients who have a more pronounced hyperandrogenic 
profile, minimal or absent insulin resistance, and pronounced 
hypertrichosis.
Ovarian morphology changes dramatically should the primum 
movens of PCOS development be insulin resistance. Normally, 
6Alviggi et al. Ultrasound in PCOS
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insulin, by way of the classic mechanism of “spill-over,” binds 
insulin growth factor-1 (IGF-1) receptor thereby exerting mito-
genic effects on the granulosa and theca. IGF-2 plays a pivotal role 
in the FSH-mediated proliferation of the granulosa and is hence 
important for the growth and development of follicles (15). If the 
proliferation of antral follicles is not finely regulated, the mecha-
nisms governing the selection of the dominant follicle could be 
deranged thereby fostering follicle atresia. Our data suggest that 
the growth of antral follicles is blocked before in PCOS women 
with insulin resistance. In fact, type B ovaries are characterized by 
a predominance of follicles with a diameter measuring between 
2 and 4 mm. In addition, lack of prominent hyperandrogenism 
could explain absence of hyperthecosis, which in turn may 
lead to a ubiquitous distribution of follicles. Although insulin 
production could reduce SHBG concentrations and so lead to 
an increase in the free forms of various androgens particularly 
testosterone (2), this effect does not seem sufficient to induce the 
hyperthecosis typical of PCOS associated with a hyperandrogenic 
pattern. Our results support this hypothesis. In fact, androgen 
levels and clinical hyperandrogenism indices were lower in our 
patients with a type B ovary and partially in the hyperinsulinemic 
patients (Tables 1 and 2).
The hypothesis that different PCOS profiles have specific 
physiopathological pathways may have important implications 
for the management of patients and might imply a revision of the 
current PCOS diagnostic criteria. In other words, the attempt of 
the Rotterdam Consensus Group (7) to define a shared, universal 
diagnosis of PCOS by gathering together patients with different 
characteristics and phenotypes may lead to a suboptimal approach 
for these patients even in fertility management. In detail, the insu-
linemic pattern seems to significantly influence ovarian response 
to gonadotropin administration (16) and ovarian drilling success 
(17). An increased risk of ovarian hyperstimulation syndrome in 
hyperinsulinemic patients has also been reported (18). The insu-
lin profile may also indirectly affect ovarian stimulation. In fact, 
insulin-sensitizing agents such as metformin before and during 
IVF/ICSI significantly reduced the incidence of ovarian hyper-
stimulation and improved the pregnancy rate (19). On the other 
hand, a hyperandrogenic profile may impair AMH production 
and lead to dysfunction of folliculogenesis (20). The higher basal 
LH levels usually observed in hyperandrogenic women could also 
influence the ovarian response (21–23). In detail, PCOS patients 
with an elevated LH/FSH ratio had a better pregnancy rate when 
treated with GnRH agonist protocols than with GnRH antagonist 
protocols, probably because the long GnRH agonist induces 
prolonged LH suppression milieu thereby avoiding the negative 
effect of higher LH levels on reproductive outcome (21, 23, 24). 
Consequently, strategies that minimize the effect of LH could be 
considered for patients with a hyperandrogenic profile.
A possible limitation of this study is the lack of a control 
population. Initially, we intended to focus on the heterogeneity 
within PCOS women according to Rotterdam criteria. Following 
confirmation of these preliminary observations, larger studies 
that include a healthy control population would be necessary 
to better define differences among groups. Another limit is the 
retrospective design per  se. Should our preliminary observa-
tions be confirmed in a prospective trial including confirmation 
of inter-reliability among operators, all the ultrasonographic 
features should be analyzed separately in order to identify the 
features most predictive of the insulin resistance.
In conclusion, we found that insulin resistance in PCOS 
patients is associated with a peculiar ultrasound pattern. This 
observation, if confirmed by larger studies, supports the concept 
that specific PCOS profiles could be identified by a complete 
metabolic evaluation and targeted ultrasound evaluation. Given 
the paucity of data regarding this issue, it remains to be seen 
if different PCOS profiles will lead to different diagnostic and 
eventually more tailored therapeutic approaches.
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